ClinicalTrials.gg
CompletedNCT06705088Updated Apr 7, 2026

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants

A Phase 1 interventional study of SUVN-I6107 and Placebo in Healthy, sponsored by Suven Life Sciences Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Suven Life Sciences Limited · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is 1) to investigate how safe and tolerable SUVN-I6107 is after a single oral dose at increasing dose levels and multiple oral doses at increasing dose levels, 2) to determine the pharmacokinetic (PK) profile after single and multiple ascending oral doses, 3) to investigate the effects of food on SUVN-I6107 pharmacokinetics and 4) to evaluate the pharmacodynamic (PD) effects of single and multiple ascending oral doses of SUVN-I6107 on quantitative electroencephalogram (qEEG) and event-related potential (ERP) assessments.

Read the detailed description

This research study is a randomized, single-center, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD), first-in-human study in healthy participants.

This study consist of 2 segments: Segment 1 will be the SAD portion and Segment 2 will be the MAD portion.

Segment 1 will include up to 5 sequential cohorts. Up to 40 healthy male or female subjects, ages 18 - 45 years (inclusive) old at screening will be enrolled.

Segment 2 will include up to 3 sequential cohorts. The dosing will be administered for 14 consecutive days. Up to 24 healthy male or female subjects, ages 50 to 80 years (inclusive) old at screening will be enrolled.

02

Conditions studied

  • Healthy

Keywords

  • SUVN-I6107
  • First-in-Human
  • Muscarinic M1 Receptor Positive Allosteric Modulator (M1-PAM)
03

In context

Lead sponsor

Suven Life Sciences Limited is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI): 18.0 to 30.0 kg/m2 for Segment 1 and 18.0 to 32.0 kg/m2 for Segment 2, inclusive, at screening and weight at least 50 kg and no more than 100 kg.
  • Ability and willingness to abstain from alcohol-, caffeine-, and methylxanthine-containing beverages or food (eg, coffee, tea, cola, chocolate, energy drinks) from 48 hours (2 days) prior to each admission to the clinical facility until study discharge.
  • All values for hematology and clinical chemistry tests of blood and urine within the normal range or showing no deviations, as judged by the Investigator, at screening and at admission.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, lactating, planning to become pregnant, or planning to donate ova/oocytes during this study or within 30 days after last administration of study drug.
  • Males with female partners who are pregnant, lactating, or planning to become pregnant during this study or within 90 days after dosing of study drug.
  • Any illness, medical/surgical procedure, or trauma within 4 weeks of admission to the clinical site.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose

    single ascending doses administered orally

    Drug: SUVN-I6107 · Drug: Placebo

  • Experimental
    Multiple Ascending Dose

    multiple ascending doses administered orally for 14 days.

    Drug: SUVN-I6107 · Drug: Placebo

Interventions

  • DrugSUVN-I6107

    SUVN-I6107 Tablet

  • DrugPlacebo

    A look-alike tablet with no active ingredient.

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events

    Number of participants with adverse events (AE), discontinuations due to AE or serious adverse event \[SAE\], and withdrawals from the study due to AE.

    Time frame: From Day 1 to Day 11 (Segment 1) and from Day 1 to Day 24 (Segment 2)

  2. Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Values

    Descriptive statistics of QTcF for observed values and changes from baseline will be summarized at each scheduled time point.

    Time frame: From Baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)

  3. Number of Participants With Clinically Significant Changes in Blood Pressure

    Time frame: From baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)

  4. Number of Participants With Clinically Significant Changes in Pulse Rate

    Time frame: From baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)

  5. Number of Participants With Clinically Significant Changes in Body Temperature

    Time frame: From baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)

  6. Number of Participants With Clinically Significant Changes in Respiration Rate

    Time frame: From baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)

  7. Changes in Columbia Suicide Severity Rating Scale (C-SSRS) Score

    The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.

    Time frame: From baseline to Day 24 (Segment 2)

Secondary outcomes

  1. Area under the concentration-time curve (AUC)

    SUVN-I6107 concentrations levels will be assessed after single and multiple ascending oral doses.

    Time frame: Day 1 and Day 14

  2. Maximum observed concentration (Cmax)

    SUVN-I6107 maximum observed concentration will be assessed after single and multiple ascending oral doses.

    Time frame: Day 1 and Day 14

  3. Time to reach maximum concentration (Tmax)

    Time to reach maximum concentration will be assessed after single and multiple ascending oral doses.

    Time frame: Day 1 and Day 14

  4. Terminal half-life (t½)

    SUVN-I6107 elimination rate will be assessed after single and multiple ascending oral doses.

    Time frame: Day 1 and Day 14

Other outcomes

  1. Quantitative electroencephalogram (qEEG)

    Change in absolute quantitative electroencephalogram (qEEG) power from predose to postdose.

    Time frame: Day 1 (Segment 1); Day 7 and Day 12 (Segment 2)

  2. Latency for parameter from the Active, Auditory Oddball Event-related potential (ERP) test

    Change in latency (in milliseconds) for the P300 parameter from the Active, Auditory Oddball ERP test from predose to postdose.

    Time frame: Day 1 (Segment 1); Day 7 and Day 12 (Segment 2)

07

Study locations

1 site
  • Clinical Research Site
    San Antonio, Texas 78209, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Dec 2025, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2024
First posted
Nov 26, 2024
StartActual
Jan 7, 2025
Primary completionActual
Dec 2, 2025
CompletionActual
Dec 2, 2025
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06705088
Lead sponsor
Suven Life Sciences Limited
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Jan 7, 2025
Primary completion
Dec 2, 2025
Completion
Dec 2, 2025
Last update
Apr 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion